Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Neurodegenerative disease

Amyloid pores from pathogenic mutations


Alzheimer's and Parkinson's diseases are associated with the formation in the brain of amyloid fibrils from β-amyloid and α-synuclein proteins, respectively. It is likely that oligomeric fibrillization intermediates (protofibrils), rather than the fibrils themselves, are pathogenic, but the mechanism by which they cause neuronal death remains a mystery. We show here that mutant amyloid proteins associated with familial Alzheimer's and Parkinson's diseases form morphologically indistinguishable annular protofibrils that resemble a class of pore-forming bacterial toxins, suggesting that inappropriate membrane permeabilization might be the cause of cell dysfunction and even cell death in amyloid diseases.


The possibility that a molecular species other than the amyloid fibril could be pathogenic arose when oligomeric species rich in β-sheet structure (protofibrils) were found to be discrete intermediates in the fibrillization of β-amyloid (Aβ) and of α-synuclein in vitro1,2. An intermediate protofibril might therefore be pathogenic and be 'detoxified' by conversion to a fibril, as suggested by three general observations: there is no correlation between the quantity of fibrillar deposits at autopsy and the clinical severity of Alzheimer's or Parkinson's disease; transgenic mouse models of these conditions have disease-like phenotypes before fibrillar deposits can be detected1,2; and non-fibrillar Aβ oligomers are toxic in cell culture3,4 and have activity in vivo5.

Toxic protofibrils have been implicated in other neurodegenerative diseases as well as in systemic amyloidoses such as type II diabetes (in which the amyloid protein is IAPP)6 and familial amyloidotic polyneuropathy (in which it is transthyretin)7. Strikingly, protofibrils comprising proteins that are not associated with any disease are also toxic, suggesting that toxicity might arise from a shared structural feature of these intermediates8.

The pathogenic-protofibril hypothesis is supported by biophysical studies of variants of Aβ and α-synuclein linked to autosomal-dominant forms of Alzheimer's and Parkinson's diseases, respectively. The 'Arctic' mutation in amyloid-precursor protein, unlike all other mutations associated with Alzheimer's disease, reduces the total concentration of circulating Aβ, but mutant AβARC forms protofibrils in vitro more rapidly and to a greater extent than the wild-type form9.

The A30P and A53T α-synuclein mutations associated with Parkinson's disease (in which an alanine residue is replaced by phenylalanine at position 30 or by threonine at position 53, respectively) both promote protofibril formation in vitro relative to wild-type α-synuclein2. We examined the structural properties of A30P, A53T and AβARC protofibrils for shared structural features that might be related to their toxicity.

Heterogeneous populations of A30P, A53T and AβARC protofibrils were fractionated by gel-filtration chromatography (H.A.L. et al., unpublished results). The fraction with the smallest A30P and A53T protofibrils contained β-sheet-rich (as measured by circular dichroism) oligomers comprising 20–25 α-synuclein molecules (relative molecular mass, 320K–380K; 22–26 monomers; H.A.L. et al., unpublished results). Analysis of this fraction by electron microscopy revealed annular species (diameter 8–12 nm; inner diameter 2.0–2.5 nm) and coiled species, both of which seemed to be related to the spherical and chain-like species reported earlier2. Protofibrillar AβARC, fractionated by a similar method, contained many annular species of similar appearance (Fig. 1), diameter (7–10 nm; inner diameter 1.5–2.0 nm) and relative molecular mass (150K–250K, 40–60 AβARC molecules).

Figure 1: Mutations that cause Alzheimer's and Parkinson's diseases promote the formation of amyloid pores.
figure 1

Projection averages of annular protofibrils formed by the Parkinson's-disease-linked α-synuclein mutants A53T and A30P and by the Alzheimer's-disease-linked Aβ(1–40)ARC 'Arctic' mutant (E22G). The images were calculated from a total of about 5,000–6,000 particles, which were obtained from 25–31 digitized electron micrographs of purified (by gel filtration on Superdex-200 (α-synuclein) or Superose-6 (Aβ)) protofibrillar fractions corresponding to the lowest-Mr fraction of each mutant. Each panel shows an original area of 30.5×30.5 nm.

The pore-like morphology of a subpopulation of amyloid protofibrils might explain the pore activity of α-synuclein protofibrils in vesicle-permeabilization models10 and the channel-like properties of Aβ (ref. 11). Other amyloid proteins, including huntingtin (in Huntington's disease)12 and IAPP6,12, also have pore-like activity in vitro. The small annular Aβ and α-synuclein protofibrils (Fig. 1) resemble the cytolytic β-barrel pore-forming toxins from bacteria such as Clostridium perfringens13.

As expected, amyloid pores are formed much less efficiently than bacterial pores, which during the course of evolution have optimized their ability to puncture host membranes. However, amyloid pores might be wholly or partly responsible for the cytotoxicity associated with the formation of amyloid fibrils in Alzheimer's and Parkinson's diseases and in other age-associated degenerative amyloid diseases.


  1. Lansbury, P. T. Proc. Natl Acad. Sci. USA 96, 3342–3344 (1999).

    ADS  CAS  Article  Google Scholar 

  2. Goldberg, M. S. & Lansbury, P. T. Nature Cell Biol. 2, E115–E119 (2000).

    CAS  Article  Google Scholar 

  3. Hartley, D. M. et al. J. Neurosci. 19, 8876–8884 (1999).

    CAS  Article  Google Scholar 

  4. Lambert, M. P. et al. Proc. Natl Acad. Sci. USA 95, 6448–6453 (1998).

    ADS  CAS  Article  Google Scholar 

  5. Walsh, D. M. et al. Nature 416, 535–539 (2002).

    ADS  CAS  Article  Google Scholar 

  6. Janson, J. et al. Diabetes 48, 491–498 (1999).

    CAS  Article  Google Scholar 

  7. Sousa, M. M. et al. Am. J. Pathol. 159, 1993–2000 (2001).

    CAS  Article  Google Scholar 

  8. Bucciantini, M. et al. Nature 416, 507–511 (2002).

    ADS  CAS  Article  Google Scholar 

  9. Nilsberth, C. et al. Nature Neurosci. 4, 887–893 (2001).

    CAS  Article  Google Scholar 

  10. Volles, M. J. & Lansbury, P. T. Biochemistry 41, 4595–4602 (2002).

    CAS  Article  Google Scholar 

  11. Lin, H., Bhatia, R. & Lal, R. FASEB J. 15, 2433–2444 (2001).

    CAS  Article  Google Scholar 

  12. Kagan, B. L., Hirakura, Y., Azimov, R. & Azimova, R. Brain Res. Bull. 56, 281–284 (2001).

    CAS  Article  Google Scholar 

  13. Hotze, E. M. et al. J. Biol. Chem. 277, 11597–11605 (2002).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Peter T. Lansbury Jr.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lashuel, H., Hartley, D., Petre, B. et al. Amyloid pores from pathogenic mutations. Nature 418, 291 (2002).

Download citation

  • Issue Date:

  • DOI:

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing